ZYBERNO
Stock Report
Updated Jun 3, 2026

TOURMALINE BIO, INC. (TRML)

Healthcare • NASDAQ

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
TOURMALINE BIO, INC. (TRML) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-30.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-277.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

TOURMALINE BIO, INC. (TRML) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, TRML generated -$84.04M in Owner Earnings. Capital was deployed as follows: $7.00K returned via share buybacks, $18.00K invested in capital expenditures. Reinvestment rate: 0.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$0.00

Enterprise Metrics (1)

Enterprise Value:-$231.55M
B. Profitability Assessment

Return Metrics (5)

ROA:-29.6%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):-0.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:-999.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-34.2%
Latest Earnings Filed:2025-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:24.68x
Quick Ratio:24.68x
Cash Ratio:22.95x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:239,006,000.00
Cash And Cash Equivalents:231,700,000.00
Long Term Debt:$8.00K
Net Debt:-$231.55M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$102.45M

Bottom Line Performance (3)

-$88.47M
Income Before Tax:$0.00
Ebitda Ttm:-102,408,000.00

Operating Expenses (5)

Operating Expenses:102,449,000.00
R And D Expense:79,767,000.00
Sga Expense:22,682,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$269.30M
Current Assets:$249.10M
Ppe Net:47,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:10,103,000.00
Current Liabilities:10,095,000.00
Long Term Debt:$8.00K
Short Term Debt:$145.00K

Equity & Capital (3)

Equity:$259.19M
Retained Earnings:-$181.32M
Common Stock:140,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,170,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,466,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$84.02M-$84.04M

Investment Activities (2)

Investing Cash Flow:$25.94M
Capital Expenditures Ttm:18,000.00

Financing Activities (3)

Financing Cash Flow:$562.00K
Dividends Paid Ttm:0.00
Stock Repurchase:7,000.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:41,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.45
-$3.45
Earnings Per Share Ttm:-$3.44

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$3.00

Book Value & Capital (2)

Book Value Per Share:$10.06
Cash Per Share:9.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$84.04M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):-0.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):7.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:TRML
Company Name:TOURMALINE BIO, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:25.76M
Shares Outstanding Basic:25.76M
Shares Outstanding Diluted:25.76M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-03 13:14:25 UTC
Data Timestamp:2026-06-03T13:14:25.796321
Scroll to Top